PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Pathways Bioscience, Aurora, CO, 80045, USA; Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA. Electronic address: joe.mccord@cuanschutz.edu.\', \'Pathways Bioscience, Aurora, CO, 80045, USA; Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA. Electronic address: brooks@pathwaysbio.com.\', \'Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA. Electronic address: adela.cota-gomez@cuanschutz.edu.\', \'Pathways Bioscience, Aurora, CO, 80045, USA; Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA. Electronic address: bifeng.gao@cuanschutz.edu.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0891-5849(21)00325-710.1016/j.freeradbiomed.2021.05.033
?:doi
?:hasPublicationType
?:journal
  • Free radical biology & medicine
is ?:pmid of
?:pmid
?:pmid
  • 34058321
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Nrf2 activator PB125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all